Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5-iodouracil - Implications for mechanism of inhibition and electron transfer

被引:52
作者
Dobritzsch, D
Ricagno, S
Schneider, G
Schnackerz, KD
Lindqvist, Y [1 ]
机构
[1] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Struct Biol, S-17177 Stockholm, Sweden
[2] Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany
关键词
D O I
10.1074/jbc.M111877200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dihydroprymidine dehydrogenase catalyzes the first and rate-limiting step in pyrimidine degradation by converting pyrimidines to the corresponding 5,6-dihydro compounds. The three-dimensional structures of a binary complex with the inhibitor 5-iodouracil and two ternary complexes with NADPH and the inhibitors 5-iodouracil and uracil-4-acetic acid were determined by x-ray crystallography. In the ternary complexes, NADPH is bound in a catalytically competent fashion, with the nicotinamide ring in a position suitable for hydride transfer to FAD. The structures provide a complete picture of the electron transfer chain from NADPH to the substrate, 5-iodouracil, spanning a distance of 56 Angstrom and involving FAD, four [Fe-S] clusters, and FMN as cofactors. The crystallographic analysis further reveals that pyrimidine binding triggers a conformational change of a flexible active-site loop in the alpha/beta-barrel domain, resulting in placement of a catalytically crucial cysteine close to the bound substrate. Loop closure requires physiological pH, which is also necessary for correct binding of NADPH. Binding of the voluminous competitive inhibitor uracil-4-acetic acid prevents loop closure due to steric hindrance. The three-dimensional structure of the ternary complex enzyme-NADPH-5-iodouracil supports the proposal that this compound acts as a mechanism-based inhibitor, covalently modifying the active-site residue Cys-671, resulting in S-(hexahydro-2,4-dioxo-5-pyrimidinyl)cysteine.
引用
收藏
页码:13155 / 13166
页数:12
相关论文
共 36 条
[1]   cDNA cloning of bovine liver dihydropyrimidine dehydrogenase [J].
Albin, N ;
Johnson, MR ;
Diasio, RB .
DNA SEQUENCE, 1996, 6 (04) :243-250
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[4]   The oral fluorinated pyrimidines [J].
de Bono, JS ;
Twelves, CJ .
INVESTIGATIONAL NEW DRUGS, 2001, 19 (01) :41-59
[5]   FAMILIAL DEFICIENCY OF DIHYDROPYRIMIDINE DEHYDROGENASE - BIOCHEMICAL BASIS FOR FAMILIAL PYRIMIDINEMIA AND SEVERE 5-FLUOROURACIL-INDUCED TOXICITY [J].
DIASIO, RB ;
BEAVERS, TL ;
CARPENTER, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (01) :47-51
[6]   Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil [J].
Dobritzsch, D ;
Schneider, G ;
Schnackerz, KD ;
Lindqvist, Y .
EMBO JOURNAL, 2001, 20 (04) :650-660
[7]   Crystallization and preliminary X-ray study of pig liver dihydropyrimidine dehydrogenase [J].
Dobritzsch, D ;
Persson, K ;
Schneider, G ;
Lindqvist, Y .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2001, 57 :153-155
[8]   An extensively modified version of MolScript that includes greatly enhanced coloring capabilities [J].
Esnouf, RM .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 1997, 15 (02) :132-+
[9]   Flavoenzymes: diverse catalysts with recurrent features [J].
Fraaije, MW ;
Mattevi, A .
TRENDS IN BIOCHEMICAL SCIENCES, 2000, 25 (03) :126-132
[10]  
HEGGIE GD, 1987, CANCER RES, V47, P2203